Premium
Pralatrexate, a novel class of antifol with high affinity for the reduced folate carrier‐type 1, produces marked complete and durable remissions in a diversity of chemotherapy refractory cases of T‐cell lymphoma
Author(s) -
O'Connor Owen A.,
Hamlin Paul A.,
Portlock Carol,
Moskowitz Craig H.,
Noy Ariela,
Straus David J.,
MacGregorCortelli Barbara,
Neylon Ellen,
Sarasohn Debra,
Dumetrescu Otila,
Mould Diane R.,
Fleischer Martin,
Zelenetz Andrew D.,
Sirotnak Frank,
Horwitz Steven
Publication year - 2007
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2007.06658.x
Subject(s) - refractory (planetary science) , chemotherapy , medicine , oncology , cancer research , pharmacology , biology , astrobiology
Summary T‐cell lymphomas (TCLs) are characterised by poor responses to therapy with brief durations of remissions. An early phase study of pralatrexate has demonstrated dramatic activity in patients with relapsed/refractory disease. Of the first 20 lymphoma patients treated, 16 had B‐cell lymphoma and four had refractory aggressive TCL. All four patients with TCL achieved a complete remission. Patients with B‐cell lymphoma achieved stable disease at best. For each TCL patient, the response was more durable than their best response with chemotherapy. This early experience is the first to document this unique activity of pralatrexate in TCL.